Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling

被引:57
作者
Jenkins, Jean
Calzone, Kathleen A. [1 ]
Dimond, Eileen
Liewehr, David J.
Steinberg, Seth M.
Jourkiv, Oxana
Klein, Pam
Soballe, Peter W.
Prindiville, Sheila A.
Kirsch, Ilan R.
机构
[1] Natl Human Genome Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Genet Branch, Bethesda, MD 20892 USA
[3] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[6] Amgen Inc, Seattle, WA USA
关键词
genetic testing; genetic counseling; BRCA1/BRCA2; result disclosure; risk communication;
D O I
10.1097/GIM.0b013e31812e6220
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: This study evaluated whether phone results were equivalent to in-person result disclosure for individuals undergoing BRCA1/2 predisposition genetic testing. Methods: A total of 111 of 136 subjects undergoing education and counseling for BRCA1/2 predisposition genetic testing agreed to randomization to phone or in-person result disclosure. Content and format for both sessions were standardized. Data from the State-Trait Anxiety Inventory and the Psychological General Well-Being index were collected at baseline and then again at 1 week and 3 months after disclosure of test results. Baseline measures were administered after the following had occurred: counseling/education session had been conducted, informed consent had been obtained, and decision to be tested had been made. Satisfaction and cost assessments were administered after the result session. At 1 week, participants were asked their preferred method of result disclosure. Results: There were no differences in anxiety and general well-being measures between 50 phone and 52 in-person results disclosure. Both groups reported similar rates of satisfaction with services. Among those with a preference, 77% preferred the notification method assigned. There was a statistically significant preference for phone results among the 23% who did not prefer the method assigned. Greater costs were associated with in-person result disclosure. Conclusions: These data suggest that phone results are a reasonable alternative to traditional in-person BRCA1/2 genetic test disclosure without any negative psychologic outcomes or compromise in knowledge. However, further study is needed in a more clinically representative population to confirm these findings.
引用
收藏
页码:487 / 495
页数:9
相关论文
共 34 条
[1]  
[Anonymous], 1996, MEASURING HLTH
[2]   GENETIC-COUNSELING FOR FAMILIES WITH INHERITED SUSCEPTIBILITY TO BREAST AND OVARIAN-CANCER [J].
BIESECKER, BB ;
BOEHNKE, M ;
CALZONE, K ;
MARKEL, DS ;
GARBER, JE ;
COLLINS, FS ;
WEBER, BL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (15) :1970-1974
[3]   Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 [J].
Bluman, LG ;
Rimer, BK ;
Berry, DA ;
Borstelmann, N ;
Iglehart, JD ;
Regan, K ;
Schildkraut, J ;
Winer, EP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1040-1046
[4]   Psychological impact of genetic counseling for familial cancer: A systematic review and meta-analysis [J].
Braithwaite, D ;
Emery, J ;
Walter, F ;
Prevost, AT ;
Sutton, S .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (02) :122-133
[5]   Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer [J].
Calzone, KA ;
Prindiville, SA ;
Jourkiv, O ;
Jenkins, J ;
DeCarvalho, M ;
Wallerstedt, DB ;
Liewehr, DJ ;
Steinberg, SM ;
Soballe, PW ;
Lipkowitz, S ;
Klein, P ;
Kirsch, IR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3455-3464
[6]  
Calzone KA, 1997, CANCER PRACT, V5, P228
[7]  
Campbell L, 1997, BRIT J SURG, V84, P1381
[8]  
Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
[9]  
2-Z
[10]   What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? [J].
Coyne, JC ;
Kruus, L ;
Racioppo, M ;
Calzone, KA ;
Armstrong, K .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 116A (03) :222-228